Inventor
PETERS KEVIN
US39 patents
⚠️ This page may combine multiple inventors who share the name “PETERS KEVIN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
EYEPOINT PHARMACEUTICALS INC
12 patentsUS11180551B2Nov 23, 2021
Humanized monoclonal antibodies that target VE-PTP (HPTP-beta)
EYEPOINT PHARMACEUTICALS INC6 citations82
US12043664B2Jul 23, 2024
Methods for treating vascular leak syndrome and cancer
EYEPOINT PHARMACEUTICALS INC1 citations73
US11873334B2Jan 16, 2024
Method of treating ocular conditions by administering an antibody that activates Tie2 and binds VEGF
EYEPOINT PHARMACEUTICALS INC2 citations73
US11666558B2Jun 6, 2023
Methods of treating intraocular pressure with activators of Tie-2
EYEPOINT PHARMACEUTICALS INC2 citations73
US11253502B2Feb 22, 2022
Tie-2 activators targeting the Schlemm's canal
EYEPOINT PHARMACEUTICALS INC3 citations73
US12145986B2Nov 19, 2024
Method of treating an ocular condition by administering a humanized monoclonal antibodies that target VE-PTP (HPTP-Beta)
EYEPOINT PHARMACEUTICALS INC1 citations71
US12544362B2Feb 10, 2026
Methods of treating acute respiratory distress syndrome with activators of Tie-2
EYEPOINT PHARMACEUTICALS INC0 citations62
US12398204B2Aug 26, 2025
Method of treating an ocular condition by administering multispecific antibodies that activates TIE2 and binds a receptor tyrosine kinase agonist
EYEPOINT PHARMACEUTICALS INC0 citations62
US12171751B2Dec 24, 2024
Methods of treating intraocular pressure with activators of Tie-2
EYEPOINT PHARMACEUTICALS INC0 citations62
US12064420B2Aug 20, 2024
Tie-2 activators targeting the Schlemm's canal
EYEPOINT PHARMACEUTICALS INC0 citations62
US11413242B2Aug 16, 2022
Formulations of Tie-2 activators and methods of use thereof
EYEPOINT PHARMACEUTICALS INC1 citations62
US12152023B2Nov 26, 2024
Compositions, formulations and methods for treating ocular diseases
EYEPOINT PHARMACEUTICALS INC0 citations61
AERPIO THERAPEUTICS INC
8 patentsUS10329357B2Jun 25, 2019
Treatment of ocular disease
AERPIO THERAPEUTICS INC16 citations94
US10220048B2Mar 5, 2019
Compositions and methods for treating ocular diseases
AERPIO THERAPEUTICS INC19 citations94
US9539245B2Jan 10, 2017
Combination of immunotherapies with activators of Tie-2
AERPIO THERAPEUTICS INC37 citations94
US8999325B2Apr 7, 2015
Treatment of ocular disease
AERPIO THERAPEUTICS INC36 citations94
US9440963B2Sep 13, 2016
Compositions, formulations and methods for treating ocular diseases
AERPIO THERAPEUTICS INC35 citations93
US10150811B2Dec 11, 2018
Methods for treating vascular leak syndrome and cancer
AERPIO THERAPEUTICS INC15 citations92
US10253094B2Apr 9, 2019
Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions
AERPIO THERAPEUTICS INC13 citations91
US9994560B2Jun 12, 2018
HPTP-β inhibitors
AERPIO THERAPEUTICS INC8 citations79
HEWLETT PACKARD DEVELOPMENT CO
6 patentsUS7163659B2Jan 16, 2007
Free-standing nanowire sensor and method for detecting an analyte in a fluid
HEWLETT PACKARD DEVELOPMENT CO91 citations97
US7410904B2Aug 12, 2008
Sensor produced using imprint lithography
HEWLETT PACKARD DEVELOPMENT CO28 citations92
US7009268B2Mar 7, 2006
Wheatstone bridge scheme for sensor
HEWLETT PACKARD DEVELOPMENT CO30 citations92
US7833801B2Nov 16, 2010
Free-standing nanowire method for detecting an analyte in a fluid
HEWLETT PACKARD DEVELOPMENT CO12 citations84
US7255805B2Aug 14, 2007
Photonic structures, devices, and methods
HEWLETT PACKARD DEVELOPMENT CO5 citations62
US7608194B2Oct 27, 2009
Photonic structures, devices, and methods
HEWLETT PACKARD DEVELOPMENT CO1 citations52
AERPIO PHARMACEUTICALS INC
4 patentsUS10894824B2Jan 19, 2021
Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
AERPIO PHARMACEUTICALS INC6 citations83
US10815300B2Oct 27, 2020
Methods for treating vascular leak syndrome and cancer
AERPIO PHARMACEUTICALS INC5 citations83
US11136389B2Oct 5, 2021
Humanized monoclonal antibodies that target VE-PTP (HPTP-β)
AERPIO PHARMACEUTICALS INC5 citations82
US10858354B2Dec 8, 2020
HPTP-Beta inhibitors
AERPIO PHARMACEUTICALS INC3 citations68
AERPIO THERAPEUTICS LLC
2 patentsUS10604569B2Mar 31, 2020
Humanized monoclonal antibodies that target protein tyrosine phosphatase-beta (HPTP-β/VE-PTP)
AERPIO THERAPEUTICS LLC12 citations92
US10597452B2Mar 24, 2020
Methods of treating ocular conditions by administering humanized monoclonal antibodies that target VE-PTP (HPTP-beta)
AERPIO THERAPEUTICS LLC11 citations92